ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.

Active
Institution
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA
Principal investigator
Samuel Jeremy Pleasure
Funding
$2.1M
Duration
2024–2029
Open portfolio

Moonbase score

Still being scored

Abstract

In this COMBINE proposal the team seeks to develop an approach to facilitate the discovery of autoantibodies directed to cell surface antigens that may be directly pathogenic. The specificity of these new autoantibodies will be deeply characterized and recombinant human monoclonal antibodies (mAbs) will be generated by single-cell sequencing. These recombinant mAbs will allow the development of animal models of disease. Tools to treat these new models in an antigen-specific manner will be pursued using novel approaches to identify neutralizing antibodies to target antibodies directly and by developing CAAR-T cells, T cell-engagers (TCE), and NK-cell Engagers (NKCEs) to target the autoantibody-producing B-cells. The proposal describes the methodologies we’ve developed to pursue this goal and how we will develop new approaches. We also describe as proof of principle a new autoantibody-dependent neuroinflammatory syndrome that will be the first target for this integrated approach.

Research team

  • Joseph L. DerisiPI
  • Samuel Jeremy PleasurePI
  • Michael R WilsonPI

LOADING MOONBASE SCORE

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKERM1Special Emphasis Panel[ZNS1 SRB-S (21)]neuroinflammatoryautoantibodiesantibodiesproof principleb-cellsrecombinantmabsautoantibody

Questions for UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.